| 22-01-07 | Delisting of AS "Olainfarm” shares from the Baltic Main list | AQ |
| 22-01-06 | Notification about results of final buy-back of shares | AQ |
| 21-12-30 | Notification about final share buy-back | AQ |
| 21-12-28 | Correction: Regarding results of a share buy-back offer | AQ |
| 21-12-28 | On substantial participation (4) - specified | AQ |
| 1 day | +7.19% |
| Manager | Title | Age | Since |
|---|---|---|---|
Juris Hmelnickis
CEO | Chief Executive Officer | 46 | 2025-12-31 |
Janis Leimanis
DFI | Director of Finance/CFO | 56 | - |
| Chief Tech/Sci/R&D Officer | - | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 2021-06-18 | |
Janis Buks
CHM | Chairman | - | 2022-08-31 |
Roberts Tavjevs
BRD | Director/Board Member | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 8/4/21 | Sell | Chief Financial Officer | 97,424 | 0.6917% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.19% | +2.67% | - | - | 148M | |
| -0.57% | +0.53% | +14.22% | +80.56% | 48.56B | |
| -1.09% | -2.37% | +63.94% | +110.49% | 35.65B | |
| -1.02% | -1.69% | -4.54% | +37.04% | 11.98B | |
| -0.91% | -0.62% | +16.38% | +89.65% | 11.95B | |
| 0.00% | +1.90% | +34.67% | +129.06% | 9.29B | |
| +0.50% | +0.58% | +19.74% | +37.94% | 6.95B | |
| +2.64% | -0.80% | +48.26% | -4.42% | 6.79B | |
| -2.23% | -2.11% | +0.36% | +218.17% | 6.7B | |
| +7.04% | +17.50% | -14.38% | +29.12% | 6.81B | |
| Average | +1.20% | +1.14% | +19.85% | +80.84% | 16.07B | |
| Weighted average by Cap. | -0.09% | +0.57% | +26.29% | +86.11% |
Employees
2,191
Sector
Pharmaceuticals
Choose MarketScreener 
